Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Breast Neoplasms 315Lymphoma 282Leukemia 227Precursor Cell Lymphoblastic Leukemia-Lymphoma 216Lymphoma, Non-Hodgkin 178Leukemia, Lymphocytic, Chronic, B-Cell 177Multiple Myeloma 174Lymphoma, Large B-Cell, Diffuse 174Lymphoma, Follicular 142Leukemia, Myeloid, Acute 136Lymphoma, Mantle-Cell 126Hodgkin Disease 125Burkitt Lymphoma 118Myelodysplastic Syndromes 110Lymphoma, Large-Cell, Immunoblastic 89Lymphoma, B-Cell, Marginal Zone 85Recurrence 67Neoplasms, Plasma Cell 62Leukemia, Myeloid, Chronic-Phase 59Neuroblastoma 56Dendritic Cell Sarcoma, Interdigitating 56Leukemia, Myeloid, Accelerated Phase 55Myeloproliferative Disorders 54Melanoma 54Congenital Abnormalities 48Neoplasms 47Leukemia, Myelomonocytic, Chronic 45Leukemia, Myelogenous, Chronic, BCR-ABL Positive 45Blast Crisis 45Lymphoma, Large-Cell, Anaplastic 44

Interventions

Alemtuzumab 2tocilizumab 1Whole-Body Irradiation 1Polymerase Chain Reaction 1Methotrexate 1In Situ Hybridization 1Immunohistochemistry 1Flow Cytometry 1Etoposide 1Emapalumab 1Dexamethasone 1Data Collection 1Cytogenetic Analysis 1Cytarabine 1Cyclophosphamide 1Calcium Dobesilate 1Blotting, Western 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphohistiocytosis, Hemophagocytic × Cyclophosphamide × Clear all
NCT00368355 2020-01-21

MOHEL

Baylor College of Medicine

Phase 2 Completed
46 enrolled 12 charts
LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphohistiocytosis, Hemophagocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡